CLINICAL TRIALS PROFILE FOR OXCARBAZEPINE
✉ Email this page to a colleague
All Clinical Trials for OXCARBAZEPINE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00050934 ↗ | Pediatric Epilepsy Study | Completed | Novartis Pharmaceuticals | Phase 3 | 2002-06-01 | This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age. |
NCT00050947 ↗ | Pediatric Epilepsy Study | Completed | Novartis Pharmaceuticals | Phase 3 | 2002-07-01 | This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age. |
NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OXCARBAZEPINE
Condition Name
Clinical Trial Locations for OXCARBAZEPINE
Trials by Country
Clinical Trial Progress for OXCARBAZEPINE
Clinical Trial Phase
Clinical Trial Sponsors for OXCARBAZEPINE
Sponsor Name